16:57 EDT Opus Genetics (IRD) files to sell 7.37M shares of common stock for holders
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
- Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
- Opus Genetics price target raised to $10 from $8 at Wedbush
- Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway
- Opus Genetics: Advancing Late-Stage Gene Therapy Pipeline and 2026 Data Catalysts Support Buy Rating and $10 Target